Biotech News
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
ir.reparerx.com2026-05-06 15:28 EST
Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities CAMBRIDGE,